These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Yilmaz Y Aliment Pharmacol Ther; 2012 Nov; 36(9):815-23. PubMed ID: 22966992 [TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease: further expression of the metabolic syndrome. Tarantino G; Saldalamacchia G; Conca P; Arena A J Gastroenterol Hepatol; 2007 Mar; 22(3):293-303. PubMed ID: 17295757 [TBL] [Abstract][Full Text] [Related]
7. [Non-alcoholic fatty liver disease--new view]. Raszeja-Wyszomirska J; Lawniczak M; Marlicz W; Miezyńska-Kurtycz J; Milkiewicz P Pol Merkur Lekarski; 2008 Jun; 24(144):568-71. PubMed ID: 18702346 [TBL] [Abstract][Full Text] [Related]
8. Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Loria P; Marchesini G; Nascimbeni F; Ballestri S; Maurantonio M; Carubbi F; Ratziu V; Lonardo A Atherosclerosis; 2014 Jan; 232(1):99-109. PubMed ID: 24401223 [TBL] [Abstract][Full Text] [Related]
9. [Alcoholic and nonalcoholic steatohepatitis: the same disease! I. Diagnosis and mechanisms]. Spahr L; Rubbia-Brandt L; Hadengue A Rev Med Suisse; 2005 Sep; 1(31):2026-8, 2030-1. PubMed ID: 16212004 [TBL] [Abstract][Full Text] [Related]
10. [Adipocytokines and nonalcoholic steatohepatitis]. Lăcătuşu C; Mihai B; Mihai C; Cijevschi-Prelipcean C; Graur M Rev Med Chir Soc Med Nat Iasi; 2009; 113(2):345-52. PubMed ID: 21495339 [TBL] [Abstract][Full Text] [Related]
11. Microcirculatory disturbances and cellular changes during progression of hepatic steatosis to liver tumors. Liebig M; Hassanzada A; Kämmerling M; Genz B; Vollmar B; Abshagen K Exp Biol Med (Maywood); 2018 Jan; 243(1):1-12. PubMed ID: 29065724 [TBL] [Abstract][Full Text] [Related]
12. Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products. Fernando DH; Forbes JM; Angus PW; Herath CB Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614491 [TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis. Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364 [TBL] [Abstract][Full Text] [Related]
14. Non-alcoholic fatty liver disease: The diagnosis and management. Abd El-Kader SM; El-Den Ashmawy EM World J Hepatol; 2015 Apr; 7(6):846-58. PubMed ID: 25937862 [TBL] [Abstract][Full Text] [Related]
18. [Role of metabolic lipases and lipotoxicity in the development of non-alcoholic steatosis and non-alcoholic steatohepatitis]. Berlanga A; Guiu-Jurado E; Porras JA; Aragonès G; Auguet T Clin Investig Arterioscler; 2016; 28(1):47-61. PubMed ID: 26049666 [TBL] [Abstract][Full Text] [Related]
19. The Natural Course of Non-Alcoholic Fatty Liver Disease. Calzadilla Bertot L; Adams LA Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27213358 [TBL] [Abstract][Full Text] [Related]